Fatty Liver Treatment Market Research: Growth Projections and Trends 2030

Uncover key drivers, emerging technologies, and competitive movements shaping the fatty liver treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Fatty Liver Treatment Market expected to reach by 2030?

The fatty liver treatment market size has seen substantial growth in recent years. It is anticipated to expand from $25.05 billion in 2025 to $26.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. This historical growth can be linked to factors such as increasing obesity rates, the rising prevalence of diabetes, enhancements in liver diagnostic tools, heightened awareness of liver health, and the expansion of hepatology clinics.

The fatty liver treatment market size is projected to show robust growth in the upcoming years. It is expected to expand to $35.67 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is fueled by the development of novel NAFLD drugs, a rise in the adoption of non-invasive diagnostics, an increase in preventive healthcare measures, the expansion of tele-hepatology services, and greater investment in liver disease research. Significant trends anticipated for this period encompass the rising prevalence of non-alcoholic fatty liver disease, an increased focus on lifestyle-based treatment approaches, the growing application of targeted drug therapies, the expansion of early liver disease screening, and the integration of digital health solutions for disease monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp

What Drivers Are Driving Adoption Within The Fatty Liver Treatment Market?

The future expansion of the fatty liver treatment market is anticipated to be driven by rising alcohol consumption. Alcohol consumption involves ingesting drinks that contain alcohol, which is a psychoactive substance known for its depressant impact on the central nervous system. This can exacerbate existing fatty liver disease and contribute to the development of more severe hepatic issues, such as alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. As an illustration, the OECD, a Paris-based intergovernmental organization, reported in November 2025 that the average per capita annual alcohol intake across its member countries was 8.5 liters of pure alcohol in 2023. Consequently, the rise in alcohol consumption is a key factor propelling the expansion of the fatty liver treatment market.

What Segments Are Included Within The Fatty Liver Treatment Market?

The fatty liver treatment market covered in this report is segmented –

1) By Treatment Type: Anti-Viral Drugs, Chemotherapy Drugs, Targeted Therapy, Anti-Fibrotic Drugs

2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases

3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Subsegments:

1) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs

2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation

3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies

4) By Anti-Fibrotic Drugs: PPAR Agonists, FXR Agonists, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Other Insulin Sensitizers

Which Competitive Trends Are Impacting The Structure Of The Fatty Liver Treatment Market?

Major companies operating in the fatty liver treatment market are concentrating on developing innovative solutions, such as next-generation metabolic-modulating biologics, to satisfy the escalating demand for effective therapies addressing the underlying mechanisms of NAFLD and NASH. These biologic treatments engage with critical metabolic and inflammatory pathways, providing a more targeted and disease-modifying method compared to traditional lifestyle-based interventions, which offer restricted therapeutic impact for advanced disease. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, released positive Phase II reports regarding efruxifermin, prescribed for the management of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It represents a distinct Fc-FGF21 fusion protein that imitates the biological actions of fibroblast growth factor 21 (FGF21), which controls various metabolic pathways and cellular processes.

Who Are The Core Companies Influencing Trends In The Fatty Liver Treatment Market?

Major companies operating in the fatty liver treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Fatty Liver Treatment Market?

North America was the largest region in the fatty liver treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Fatty Liver Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12581&type=smp

Browse Through More Reports Similar to the Global Fatty Liver Treatment Market 2026, By The Business Research Company

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Liver Diseases Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Metastases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-metastases-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795